Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s D&A?
- Xeris Biopharma Holdings, Inc. (XERS) reported D&A of $323K in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s D&A changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s D&A decreased by 0.6% year-over-year, from $325K to $323K.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s D&A?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s D&A has grown at a -0.3% compound annual growth rate (CAGR), from $1.33M to $1.31M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Xeris Biopharma Holdings, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude